Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as JANSSEN BIOTECH. It is marketed under 1 brand name, including AKEEGA. Available in 2 different strengths, such as 500MG;EQ 50MG BASE, 500MG;EQ 100MG BASE, and administered through 1 route including TABLET;ORAL.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
Strength | Route of Administration | Companies | Latest Approval Date |
---|
Patents approved by the FDA for the ingredient
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
---|---|---|---|---|---|
{"application_id":"36741","ingredient":"ABIRATERONE ACETATE; NIRAPARIB TOSYLATE","trade_name":"AKEEGA","family_id":"926ec6e88a4a4e729f31","publication_number":"US8071579B2","cleaned_patent_number":"8071579","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-08-12","publication_date":"2011-12-06","legal_status":"Granted"} | US8071579B2 | 06 Dec, 2011 | Granted | 12 Aug, 2027 | |
{"application_id":"36742","ingredient":"ABIRATERONE ACETATE; NIRAPARIB TOSYLATE","trade_name":"AKEEGA","family_id":"926ec6e88a4a4e729f31","publication_number":"US8143241B2","cleaned_patent_number":"8143241","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-08-12","publication_date":"2012-03-27","legal_status":"Granted"} | US8143241B2 | 27 Mar, 2012 | Granted | 12 Aug, 2027 | |
{"application_id":"39763","ingredient":"ABIRATERONE ACETATE; NIRAPARIB TOSYLATE","trade_name":"AKEEGA","family_id":"36df53f8d5244870a6dd","publication_number":"US8436185B2","cleaned_patent_number":"8436185","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-04-24","publication_date":"2013-05-07","legal_status":"Granted"} | US8436185B2 Molecular Formulation | 07 May, 2013 | Granted | 24 Apr, 2029 | |
{"application_id":"39781","ingredient":"ABIRATERONE ACETATE; NIRAPARIB TOSYLATE","trade_name":"AKEEGA","family_id":"6a13c9e41c6e46e8aabf","publication_number":"US8071623B2","cleaned_patent_number":"8071623","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-03-27","publication_date":"2011-12-06","legal_status":"Granted"} | US8071623B2 Molecular Formulation | 06 Dec, 2011 | Granted | 27 Mar, 2031 | |
{"application_id":"35804","ingredient":"ABIRATERONE ACETATE; NIRAPARIB TOSYLATE","trade_name":"AKEEGA","family_id":"ff530a092cee43339847","publication_number":"US8859562B2","cleaned_patent_number":"8859562","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-08-04","publication_date":"2014-10-14","legal_status":"Granted"} | US8859562B2 | 14 Oct, 2014 | Granted | 04 Aug, 2031 | |
{"application_id":"111544","ingredient":"ABIRATERONE ACETATE; NIRAPARIB TOSYLATE","trade_name":"AKEEGA","family_id":"db49ef0a362b43fda4ed","publication_number":"US11992486B2","cleaned_patent_number":"11992486","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-07-28","publication_date":"2024-05-28","legal_status":"Granted"} | US11992486B2 | 28 May, 2024 | Granted | 28 Jul, 2037 | |
{"application_id":"30253","ingredient":"ABIRATERONE ACETATE; NIRAPARIB TOSYLATE","trade_name":"AKEEGA","family_id":"db49ef0a362b43fda4ed","publication_number":"US11207311B2","cleaned_patent_number":"11207311","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-07-28","publication_date":"2021-12-28","legal_status":"Granted"} | US11207311B2 | 28 Dec, 2021 | Granted | 28 Jul, 2037 | |
{"application_id":"111228","ingredient":"ABIRATERONE ACETATE; NIRAPARIB TOSYLATE","trade_name":"AKEEGA","family_id":"db49ef0a362b43fda4ed","publication_number":"US11986468B2","cleaned_patent_number":"11986468","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-07-28","publication_date":"2024-05-21","legal_status":"Granted"} | US11986468B2 | 21 May, 2024 | Granted | 28 Jul, 2037 | |
{"application_id":"112892","ingredient":"ABIRATERONE ACETATE; NIRAPARIB TOSYLATE","trade_name":"AKEEGA","family_id":"db49ef0a362b43fda4ed","publication_number":"US11986469B2","cleaned_patent_number":"11986469","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-07-28","publication_date":"2024-05-21","legal_status":"Granted"} | US11986469B2 | 21 May, 2024 | Granted | 28 Jul, 2037 | |
{"application_id":"37991","ingredient":"ABIRATERONE ACETATE; NIRAPARIB TOSYLATE","trade_name":"AKEEGA","family_id":"c5f876a72bbc4d87a4fd","publication_number":"US11091459B2","cleaned_patent_number":"11091459","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-03-27","publication_date":"2021-08-17","legal_status":"Granted"} | US11091459B2 Molecular Formulation | 17 Aug, 2021 | Granted | 27 Mar, 2038 | |
{"application_id":"37992","ingredient":"ABIRATERONE ACETATE; NIRAPARIB TOSYLATE","trade_name":"AKEEGA","family_id":"c5f876a72bbc4d87a4fd","publication_number":"US11673877B2","cleaned_patent_number":"11673877","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-03-27","publication_date":"2023-06-13","legal_status":"Granted"} | US11673877B2 Molecular Formulation | 13 Jun, 2023 | Granted | 27 Mar, 2038 |
Latest clinical trials and research studies for this ingredient
NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
---|
Manufacturing Locations
Unlock access to all suppliers of Abiraterone Acetate; Niraparib Tosylate
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.